Michael S Cookson
Overview
Explore the profile of Michael S Cookson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
218
Citations
5412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shore N, Nielsen S, Esplin E, Antonarakis E, Barata P, Beer T, et al.
JCO Oncol Pract
. 2024 Dec;
OP2400626.
PMID: 39700441
Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become...
2.
Shore N, Cookson M, Efstathiou E
Future Oncol
. 2024 Nov;
20(40):3351-3354.
PMID: 39555581
In this podcast discussion, we review the landscape of androgen deprivation therapies (ADT) for the treatment of advanced prostate cancer. Prior to 2020, available ADT options to achieve chemical castration...
3.
De La Cerda J, Thorley J, Sieber P, Cookson M, Flanders S, Gatoulis S, et al.
Future Oncol
. 2024 Nov;
21(1):51-62.
PMID: 39503549
What Is This Summary About?: Advanced prostate cancer is a cancer that began in the prostate (a part of the male body) and has spread to other parts of the...
4.
Bryce A, Crawford E, Agarwal N, Hussain M, Beltran H, Cooperberg M, et al.
JU Open Plus
. 2024 May;
2(4).
PMID: 38774467
Background: Management strategies for metastatic castration-resistant prostate cancer (mCRPC) have rapidly shifted in recent years. As novel imaging and therapeutic approaches have made their way to the clinic, providers are...
5.
Crawford E, Bryce A, Hussain M, Agarwal N, Beltran H, Cooperberg M, et al.
JU Open Plus
. 2024 May;
2(4).
PMID: 38774466
Purpose: Castration-sensitive prostate cancer (CSPC) is a complex and heterogeneous condition encompassing a range of clinical presentations. As new approaches have expanded management options, clinicians are left with myriad questions...
6.
Narayan V, Boorjian S, Alemozaffar M, Konety B, Shore N, Gomella L, et al.
J Urol
. 2024 May;
212(1):74-86.
PMID: 38704840
Purpose: Nadofaragene firadenovec-vncg is a nonreplicating adenoviral vector-based gene therapy for bacillus Calmette-Guérin (BCG)-unresponsive carcinoma in situ (CIS) with/without high-grade Ta/T1. We report outcomes following 5 years of planned follow-up....
7.
Shore N, Antonarakis E, Ross A, Marshall C, Stratton K, Ayanambakkam A, et al.
Prostate Cancer Prostatic Dis
. 2024 Apr;
PMID: 38643308
No abstract available.
8.
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer
Spratt D, George D, Shore N, Cookson M, Saltzstein D, Tutrone R, et al.
JAMA Oncol
. 2024 Mar;
10(5):594-602.
PMID: 38451492
Importance: Combination androgen deprivation therapy (ADT) with radiotherapy is commonly used for patients with localized and advanced prostate cancer. Objective: To assess the efficacy and safety of the oral gonadotropin-releasing...
9.
Shore N, Antonarakis E, Ross A, Marshall C, Stratton K, Ayanambakkam A, et al.
Prostate Cancer Prostatic Dis
. 2024 Mar;
PMID: 38431761
Background: With the availability of second-generation androgen receptor inhibitors (SGARIs), the treatment landscape has changed dramatically for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). In clinical trials, the SGARIs (apalutamide,...
10.
Lopez-Beltran A, Cookson M, Guercio B, Cheng L
BMJ
. 2024 Feb;
384:e076743.
PMID: 38346808
Bladder cancer remains a leading cause of cancer death worldwide and is associated with substantial impacts on patient quality of life, morbidity, mortality, and cost to the healthcare system. Gross...